ALPS ETF Trust has recently filed its NPORT-P report, providing a detailed overview of the financial status of its ALPS International Sector Dividend Dogs ETF. This filing, dated October 29, 2026, is crucial as it outlines the fund's asset management strategies and performance metrics, which are essential for current and potential investors.
The report indicates that the fund has total net assets of approximately $572.99 million, with total liabilities reported at $240,557.61. This substantial asset base reflects the fund's ability to attract investments and manage them effectively in a competitive market.
Background
ALPS ETF Trust, identified under the Central Index Key (CIK) 0001414040, operates in the investment sector. The company is known for its focus on exchange-traded funds (ETFs), which allow investors to gain exposure to various sectors and investment strategies. The latest filing is part of a series of NPORT-P submissions, with multiple filings made on the same date, indicating active management and reporting practices.
What the Filing Says
According to the filing, the ALPS International Sector Dividend Dogs ETF has shown a total asset value of $573,228,476.89. The report also notes that the fund's monthly total return for the last reporting period was -4.03%, with a net realized gain of approximately $8.95 million.
Impact
This update may significantly impact various stakeholders, including current investors, potential investors, and competitors within the ETF industry. The detailed financial metrics provided in the filing can serve as a benchmark for performance comparisons against other funds in the investment sector.
What's Next
The filing does not specify what happens next for ALPS ETF Trust or its funds. However, investors and analysts will likely monitor future filings for updates on performance and any strategic changes in fund management.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






